Literature DB >> 9595405

Relative contribution of endothelin A and endothelin B receptors to vasoconstriction in small arteries from human heart and brain.

L N Pierre1, A P Davenport.   

Abstract

Endothelin (ET) has been implicated in cardiovascular disorders such as stroke and myocardial ischemia. Given the important role of the resistance vasculature in the control of blood flow, we investigated the ET receptors that mediate vasoconstriction in human small pial and coronary arteries supplying the brain and heart, respectively. ETA receptors were localized by autoradiography to the vascular smooth-muscle layer of pial, intracerebral, and intramyocardial arteries. In contrast, little ETB binding was observed. ET-1 was a more potent constrictor than ET-3 in both pial and coronary arteries. Biphasic ET-3 responses were obtained in four of 15 coronary arteries tested. The ETB agonist sarafotoxin S6c had little or no effect in these vessels. The nonpeptide, selective ETA receptor antagonist PD156707 caused a parallel shift to the right of the concentration-response curve to ET-1, yielding pA2 values of 9.17 +/- 0.07 and 8.38 +/- 0.17 in pial and coronary arteries, respectively. Slopes from Schild analysis were not significantly different from unity. These data suggest that ETA receptors predominate on the smooth-muscle layer of human small pial arteries. Coronary arteries also express mainly ETA receptors. However, a small population of contractile ETB receptors may also be present in some patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9595405     DOI: 10.1097/00005344-199800001-00024

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Metabolic syndrome and endothelin-1 mediated vasoconstrictor tone in overweight/obese adults.

Authors:  Natalia G Rocha; Danielle L Templeton; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza
Journal:  Metabolism       Date:  2014-04-18       Impact factor: 8.694

Review 2.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 3.  Endothelin in heart failure.

Authors:  G Sütsch; M Barton
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

4.  Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man.

Authors:  R R Wenzel; J Rüthemann; H Bruck; R F Schäfers; M C Michel; T Philipp
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

5.  Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults.

Authors:  Brian L Stauffer; Christian M Westby; Jared J Greiner; Gary P Van Guilder; Christopher A Desouza
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-25       Impact factor: 3.619

6.  Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.

Authors:  Stephanie W Watts; Gregory D Fink; Carrie A Northcott; James J Galligan
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 7.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.